HeraMED is an Israeli company founded in 2011. Its flagship product is HeraBEAT, smartphone-based, efficient fetal heartbeat monitoring system for expectant mothers. As on 12th December, the company successfully completed its IPO of $6 million (NIS 15.8 million) at A$0.20 per share and subsequently listed on ASX.
Register Now
Get a call to receive stock recommendation services from Kalkine Pty Ltd (www.kalkine.com.au)